RxDoctor Payments Data

Melissa Kobito

Family · New Hartford, NYNPI 1912690793

Payments from drug & device makers

$4,892in general payments, 2019–2025

Across 278 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$792
  • Johnson & Johnson$744
  • Madrigal Pharmaceuticals$496
  • Takeda Pharmaceuticals U.S.A., Inc.$268
  • Phathom Pharmaceuticals, Inc.$258
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$4,881100%
  • Education$100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,892 in reported general payments places this provider in the 90th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$24,148
Medicare patients
182
Services billed
310

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide63$45,129
CreonLipase/Protease/Amylase11$28,435
TrulancePlecanatide27$16,204
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates97$6,069
Dexlansoprazole DrDexlansoprazole23$6,064
Colestipol Hcl36$2,572
Lubiprostone14$1,481
Omeprazole86$1,004
Sucralfate36$979
Famotidine89$872
Pantoprazole Sodium94$795

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$1,009$73,56374 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$792$16,20427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,883 family providers in New York.

Other family in New Hartford

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →